ACELEROX is developing novel antioxidant nanoparticles that serve as therapies for reactive oxygen species (ROS)-mediated disease. ROS has been implicated in the progression of a broad range of diseases, including rheumatoid arthritis, multiple sclerosis, ischemic stroke, traumatic brain injury, and Alzheimer’s disease. Our proprietary class of molecules, termed PEG-HCCs (PEGylated hydrophilic carbon clusters), were developed and produced in Dr. James Tour’s laboratory at Rice University next to the Texas Medical Center, and can be used to directly treat the symptoms of these diseases and to deliver chemotherapeutic drugs into tumors. When compared to other therapeutic antioxidants, PEG-HCCs are superior in that they preferentially scavenge superoxide and hydroxyl radicals, exhibit potent yet selective antioxidant activity, are unreactive with nitric oxide, are not rapidly inactivated, nor do they require assistance from auxiliary molecules. We have demonstrated efficacy in animal models of rheumatoid arthritis, traumatic brain injury, hearing loss, multiple sclerosis and Alzheimer’s disease.
Contact us for more information.